Evkeeza Market Report 2026

Evkeeza Market Overview

• The Evkeeza market growth in the historic period has been driven by limited effectiveness of traditional statins, historical burden of familial hypercholesterolemia • Market expansion is supported by increasing genetic screening for lipid disorders, rising adoption of biologics • Growth Driver: Growth Of The Evkeeza Market Driven By Increasing Genetic Disorders • Market Trend: Regulatory Approval Of Evkeeza Expands Treatment Options For Young Children With Hofh • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Evkeeza Market?

Evkeeza (evinacumab) is a monoclonal antibody used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing high cholesterol levels. It works by inhibiting angiopoietin-like 3 (ANGPTL3), helping lower LDL cholesterol and other lipid levels in affected patients. The main types of indications in evkeeza are primary hypercholesterolemia and homozygous familial hypercholesterolemia. Primary hypercholesterolemia refers to elevated levels of cholesterol in the blood due to genetic or hereditary factors rather than secondary causes like lifestyle or other medical conditions. It can be administered through intravenous (IV) infusion, self-administration, subcutaneous (SC) administration, hospital infusion centers, and infusion in ambulatory care settings and is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies.

What Is The Evkeeza Market Growth Forecast?

The growth in the forecast period can be attributed to increasing genetic screening for lipid disorders, rising adoption of biologics, expanding reimbursement for rare diseases, advancements in lipid metabolism research, growing specialty cardiology centers. Major trends in the forecast period include expansion of monoclonal antibody therapies, rising focus on rare lipid disorders, growth in precision lipid lowering treatments, increasing use of targeted angptl3 inhibitors, improved outcomes in severe hypercholesterolemia.

Global Evkeeza Market Segmentation

1) By Indication: Primary Hypercholesterolemia, Homozygous Familial Hypercholesterolemia 2) By Route Of Administration: Intravenous (IV) Infusion, Self-Administration, Subcutaneous (SC) Administration, Hospital Infusion Centers, Infusion In Ambulatory Care Settings 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies

What Are The Drivers Of The Evkeeza Market?

The increasing prevalence of genetic disorders is anticipated to drive the growth of the evkeeza market in the future. Genetic disorders are diseases or conditions caused by abnormalities in an individual's DNA, which can result from mutations in one or more genes or changes in the structure or number of chromosomes. The rise in genetic disorders is due to improved diagnostic technologies and increased environmental factors that contribute to genetic conditions. Evkeeza is used to treat homozygous familial hypercholesterolemia (HoFH), a genetic disorder, by inhibiting ANGPTL3 to lower LDL cholesterol levels in patients with this condition. For instance, in June 2024, according to the American Society of Hematology, a US-based non-profit organization, by 2050, the global population of individuals with sickle cell disease (SCD) is projected to grow by approximately 30 percent. Therefore, rising genetic disorders are driving the growth of the evkeeza industry. The growing number of drug approvals is anticipated to drive the expansion of the evkeeza market in the coming years. Drug approvals refer to the formal process by which regulatory authorities evaluate and authorize the use of pharmaceutical drugs for public consumption. The rise in drug approvals is largely attributed to advancements in biotechnology enabling faster drug discovery and supportive regulatory frameworks like accelerated approval programs streamlining the process for high-need medications. Drug approvals drive the evkeeza by expanding its availability for treating homozygous familial hypercholesterolemia, increasing patient access, and leveraging incentives like orphan drug exclusivity. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, In 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, increasing the number of drug approvals is driving the growth of the evkeeza industry.

Key Players In The Global Evkeeza Market

Major companies operating in the evkeeza market are Regeneron Pharmaceuticals Inc.

Global Evkeeza Market Trends and Insights

The key trend in the evkeeza market is obtaining regulatory approvals for drugs to expand its reach and solidify its position in the treatment of patients with homozygous familial hypercholesterolemia (HoFH). Regulatory approvals refer to the formal authorization granted by governmental or regulatory bodies for a drug, medical device, or treatment to be marketed and used by the public. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Evkeeza (evinacumab-dgnb) for young children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing extremely high LDL cholesterol levels. This marks the first approval of an ANGPTL3 inhibitor for this age group, providing a new treatment option for approximately 1,300 affected individuals in the U.S. Clinical trials showed that children treated with evkeeza alongside other lipid-lowering therapies experienced an average 48% reduction in LDL-C levels after 24 weeks.

Regional Insights

North America was the largest region in the evkeeza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Evkeeza Market?

The evkeeza market consists of sales of products including Repatha (evolocumab), Praluent (alirocumab), and Lomitapide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Evkeeza Market Report 2026?

The evkeeza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the evkeeza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.